Naloxegol, an opioid antagonist, is used to treat adult patients with chronic, non-cancerous pain who experience OIC Pipeline Drugs Market.
Nektar Therapeutics developed the medication using its own oral small molecule polymer conjugate technology. In September 2009, the drug was in-licensed by AstraZeneca as part of a drug development program.
In September 2013, AstraZeneca submitted a new drug application (NDA) for the medication to the US Food and Drug Administration (FDA), and that application was approved in September 2014. In March 2015, the company and Daiichi Sankyo worked together to make the drug available for sale in the United States.
For more target insights on OIC Pipeline Drugs Market, download a free report sample
In December 2014, the medication was granted approval in the European Union (EU) under the brand name MoventigTM. In March 2016, AstraZeneca and Kyowa Hakko Kirin's ProStrakan Group worked together to market the drug in the EU, Iceland, Norway, Switzerland, and Liechtenstein.
Movantik is a film-coated, mauve-colored, oval, biconvex tablet that should be taken once daily by mouth. It comes in strengths of 12.5mg and 25mg.
Causes and signs of opioid-induced constipation Opioid-induced constipation is the most common side effect of opioid therapy. Between 15% and 90% of patients with chronic pain unrelated to cancer are affected by the condition.
Opioids are used to treat pain for millions of people because they help with chronic pain. Opioid-induced constipation occurs when an opioid binds to mu-opioid receptors in the gastrointestinal tract.
Dry and hard stools, abdominal bloating and tenderness, difficulty defecating, nausea, and vomiting are some common signs of opioid-induced constipation.